New Delhi, Jun 18 (PTI) Zydus Lifesciences Ltd on Wednesday said the USFDA has closed follow-up inspection of its oncology injectable site near Matoda in Ahmedabad with two observations.

The US Food and Drug Administration (USFDA) had conducted a GMP follow-up inspection at the company's oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad, from June 9-18, 2025, the company said in a regulatory filing.

Also Read | Bengaluru Water Cut: BWSSB Announces 24-Hour Water Supply Disruption on June 19 Amid Urgent Cauvery Pipeline Work; Check Timings and List of Affected Areas.

"The inspection is closed with two observations, and none of them were related to data integrity," it added.

Zydus Lifesciences further said it will closely work with the USFDA to address and respond to the observations in an expeditious manner.

Also Read | Ayatollah Khamenei India Connection: Iran Supreme Leader Traces His Roots to Uttar Pradesh.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)